Human Genome Downgraded

ThinkEquity downgraded Human Genome Sciences Inc. (Nasdaq: HGSI) sending the stock price down 33 cents to close at $2.82.

About this Entry

This page contains a single entry by published on June 5, 2009 2:41 PM.

Sales Dropped For Hansen Natural was the previous entry in this blog.

FDA Approves Angiotech's Pulmonary Embolism Device is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12